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Association Between 18F-Fluoro-2-Deoxy-D-Glucose Uptake
Values and Tumor Vitality: Prognostic Value of Positron
Emission Tomography in Early-Stage Non-small Cell Lung
Cancer
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Introduction: The prognostic value of quantitative 18F-fluoro-2-
deoxy-D-glucose (FDG) uptake on positron emission tomography
(PET) is controversial in unselected patients with non-small cell
lung cancer (NSCLC). We assessed the in vivo FDG uptake,
measured as maximum pixel standardized uptake value (SUVmax),
in stages I and II NSCLC for its prognostic value and association
with in vitro quantitative morphology of tumor vitality.
Methods: Prospective FDG-PET data were available in 91 consec-
utive patients operated for pathologic stages I and II NSCLC.
Quantitative morphology was performed of tumor architecture, tu-
mor cell density and immunohistochemical biomarkers for apoptosis
(caspase-3), cell proliferation (Ki-67), hypoxia (HIF-1), cellular
pH regulation (carbonic anhydrase IX [CAIX]), and microvessel
density (CD31).
Results: SUVmax  median and SUVmax partial volume corrected
for lesion size (PVC SUVmax)  median were associated with an
increased risk of death in univariable analysis. After correcting for
stage, tumor size and age in multivariable analysis, only PVC
SUVmax  median remained significant. The strong significant
association between tumor size and SUVmax weakened after PVC,
suggesting that an important amount of SUVmax can be simply
explained by tumor size, which is less in case for PVC SUVmax that
associates more to the tumor cell density. In multivariable logistic
regression analysis, a PVC SUVmaxmedian could be explained by
high Ki-67 and high-CAIX length density.
Conclusion: PVC SUVmax has a prognostic value in completely
resected stages I and II NSCLC. A high-quantitative FDG uptake is
associated with characteristics of tumor vitality such as high tumor
cell density, high cell proliferation, and extracellular acidosis.
KeyWords: FDG-PET scan, Non-small cell lung cancer, Prognosis,
SUV.
(J Thorac Oncol. 2009;4: 822–828)
In 1930, Warburg1 considered the shift in energy productionfrom oxidative phosphorylation to glycolysis as a funda-
mental characteristic of a cancer cell. Dedicated positron
emission tomography (PET) using 18F-fluoro-2-deoxy-D-
glucose (FDG), a functional imaging technique taking advan-
tage of this glycolytic shift, became an innovative noninva-
sive clinical cancer imaging for the diagnosis and the staging
of non-small cell lung cancer (NSCLC). FDG is a glucose
analog, which shows enhanced cellular uptake as a result of
the elevated expression of the glucose transporter proteins
(GLUTs) in most cancer cells. Once in the cancer cell, FDG
is phosphorylated to FDG-6-PO4 that cannot be further me-
tabolized in the glycolytic pathway, thereby rendering cancer
cells detectable using PET.
NSCLC is a group of carcinomas with variable biologic
aggressiveness and prognosis. Clinicopathologic tumor, node,
metastasis (TNM)-stage is still the most powerful prognostic
factor, but even the most favorable stages, i.e., pathologic stages
I and II have a 30 to 40% and 45 to 60% risk of death within 5
years after resection, respectively. Therefore, better prognostic
factors are warranted. During the last decade, several retrospec-
tive analyses and one literature-based meta-analysis found that
metabolic imaging relying on maximum pixel standardized
uptake value (SUVmax) of the primary tumor on FDG-PET was
a significant and independent prognostic factor in patients with
NSCLC.2–6 But recently, these findings also became controver-
sial when a large prospective7 and retrospective8 study con-
cluded that the prognostic role of FDG-PET seemed to be of
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limited value in patients with NSCLC populations. Moreover,
no clear cutoff point was found as many factors may cause
methodological variability in SUV measurements across differ-
ent centers (such as patient preparation procedures, scan acqui-
sition, image reconstruction, and data analysis settings), and the
relationship between the cancer cell physiology and quantitative
FDG uptake on PET is less understood. Many different biologic
processes may affect FDG uptake by NSCLC on both the
cellular and tissue level. On the cellular level, glucose uptake is
mediated by the expression of GLUT9–11 and hexokinase-II
activity,11 and glucose demand is enhanced by cellular prolifer-
ation (which is related to Ki-67 or proliferating cell nuclear
antigen expression),9,12,13 alterations of tumor suppressor
genes14 and the expression of hypoxia-inducible-factor 1 (HIF-
1).15 On the tissue level, glucose delivery is a function of tumor
perfusion that is associated with angiogenesis, anatomically
reflected by microvessel density.16 Moreover, the rate of glucose
metabolism may be influenced by the presence of necrosis, reflect-
ing that proliferation outnumbers metabolic supply, or the pres-
ence of lymphocytes and macrophages that may be confounding
active metabolic cells. Additionally, tumor cells (TC) and the
tumor-associated stroma (with its inflammatory interstitium,
fibrocollagenous interstitium, and vasculature) should be seen as
a functional domain with a metabolic cooperation between
cancer cells and newly formed fibroblasts and vessels.17
As the evidence for the prognostic value of FDG uptake
remains limited when all stages of NSCLC are considered, we
conducted this translational analysis within surgically treated
stages I and II NSCLC to explore the mechanisms why quanti-
tative FDG uptake on PET may stratify patients for prognosis.
We aimed to explore the potential of FDG uptake as a prognostic
factor for outcome and a predictive factor for phenotyping tumor
vitality. Unlike most other studies, we performed quantitative
morphology of tumor architecture and quantitative immuno-
staining for cell proliferation (Ki-67 expression), tumor hypoxia
(nuclear HIF-1 expression), tumor pH regulation (membranous
carbonic anhydrase IX [CAIX]), cellular apoptosis (caspase-3
expression), and neoangiogenesis (CD31microvessel density) in
this study. Other factors possibly influencing FDG uptake such
as tumor cell density and tumor size were also investigated.
PATIENTS AND METHODS
Patients
The surgical specimens of 91 consecutive patients with
NSCLC (78 males, 13 females) undergoing baseline state of
the art preoperative staging including FDG-PET scan and
subsequently a thoracotomy with complete resection and
systematic mediastinal lymph node dissection for pathologic
stages I or II at University Hospitals Leuven (n  56) and
Maastricht (n  35). The UICC classification (TNM, 6th
edition, 2002) was used for pathologic staging. Only patients
with pure NSCLC histology (adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma) were included. No
adjuvant chemotherapy was given. Overall survival fol-
low-up was obtained by patient records or by phone contact
with the referring physicians.
Dedicated FDG-PET Scan
FDG-PET scans in Leuven were performed on a CTI-
Siemens (Iselin, NJ) 931/08/12 PET scanner, having an axial
field of view of 10.1 cm and spatial resolution of 8 mm. The
patient was positioned with the primary tumor in the filed of
view of the rectilinear PET camera. Then, a transmission scan
was performed before (cold transmission) to FDG injection
(6.5 MBq/kg, max. 555 MBq). After FDG injection, the
patient remained positioned into the PET camera, and a
60-minute dynamic study of the thorax was started, followed
by a 10-minute static acquisition over the primary tumor. The
standardized uptake values (SUV) of the primary tumor was
calculated 60 minutes postinjection. Patients from Maastricht
were scanned with an ECAT EXACT 922 CTI-Siemens
(Knoxville, TN) PET scanner in Aachen, having an axial field
of view of 16.2 cm and spatial resolution of 6 mm. A
transmission scan was also performed before FDG injection
(3.5 MBq/kg) and after a median time of 60 minutes after
injection 2-D whole body emission images were acquired.
For the determination of the SUV, a volumetric Region
of Interest was drawn around the primary tumor on the
transaxial images. The SUV was then automatically calcu-
lated as activity concentration of FDG uptake divided by the
injected dose/body weight, and the pixel with the maximum
SUV was considered the SUVmax. Partial volume effects,
caused by the limited sampling (at the level of a pixel size)
and resolution of the PET scanner, result in underestimation
of the regional FDG uptake, predominantly in tumors smaller
than twice the resolution of the PET scanner. For appropriate
partial volume correction (PVC), the necessary recovery
coefficients were determined from a software phantom based
on the spatial resolution and pixel size of the PET scanner
used. The spatial resolution depends on the full width at half
maximum (FWHM) of the PET device (for Leuven FWHM
13 mm and for Aachen FWHM of 7 mm). We took the largest
diameter of the macroscopic lesion on resection to determine
the tumor size. Finally, we used the PVC algorithm used by
Vesselle et al.12 to correct the SUVmax of lesions 40 mm.
PVC SUVmax  (SUVmax measured  0.25)
Recovery Coefficient

 0.25 (ref. 12)
Because of technical differences in methodology for PET
scanning between Leuven and Maastricht, we did not com-
bine the absolute SUVmax values of both data sets. Instead we
dichotomized the patient groups from Leuven and Maastricht
based on their respective median SUVmax value. Thereafter,
we combined the group of patients with “SUVmax  median”
from Leuven and those with SUVmax  median from Maas-
tricht and considered this group as the “low SUVmax group.”
The same was done for patients with a “SUVmax  median,”
which were considered as the “high SUVmax group.”
Quantitative Morphology of Tumor
Architecture and Immunohistochemistry
Tumor analysis was performed on histologic sections
stained with hematoxylin and eosin (H&E) from resection
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specimens archived at the pathology department. From each
tumor two to seven H&E sections and corresponding tissue
blocks were available. An H&E section of 4-m thickness,
often the largest one, was chosen for quantitative analysis.
According to the principles of stereology of biologic material
outlined by Weibel,18 the tumor was divided in compartments
of interest related to the investigation of functional metabolic
FDG-PET data: TC, fibroblastic connective tissue, necrosis,
inflammatory interstitium (INF), and a “residu.” The sum of
all compartments represents 100% of the tumor and tumor
architecture. The proportion of each compartment was ob-
tained by a conventional morphometric method based on a
point-counting technique using a Zeiss light microscope
equipped with an eyepiece containing a reticulated counting
frame and unbiased counting rule.19 The tumor cell density
was counted on a H&E section using a test line, which was
randomly located.
From the original paraffin-embedded tissue block se-
lected for quantitative analysis serial sections of 4-m thick-
ness were prepared for immunohistochemical stainings. Tu-
mor cells were stained for caspase-3 (a protease playing an
important role in the distal effector pathway for apoptosis),
Ki-67 (a proliferation marker), and endogeneous surrogate
markers of hypoxia (HIF-1) and pH regulation (CAIX),
whereas vessels and microvessels were stained for with an
endothelial marker CD31.
KI-67 and Caspase-3
We used monoclonal mouse antihuman MIB-1 antibod-
ies (Ki-67 antigen DAKO M7240, 1:100, 45 minutes) and
antihuman caspase-3 (Cell Signaling, polyclonal, 1:50, 30
minutes). The surface density of the caspase-3 and Ki-67
immunostainings was assessed using an unbiased counting
frame and unbiased counting rules and this surface density,
corrected for the proportion of tumor cells (% TC), was
transformed into a length density.
CAIX and HIF-1
We used the mouse monoclonal antihuman CAIX anti-
body M75 (Slovak Academy of Sciences, Bratislava, 1:50, 45
minutes) and the mouse monoclonal antihuman HIF-1 anti-
body (BD Biosciences Pharmingen, 1:50, overnight). The CAIX
length density was obtained by multiplying the tumor cell
density by the proportion of membranous CAIX positivity. The
surface density of HIF-1 immunostaining, corrected for the
proportion of TC, was transformed into a length density.
CD31
Blood vessels on histologic sections were stained with a
CD31 monoclonal antibody (DAKO Cytomation, 1:50, 30 min-
utes). The surface density of the microvessels was measured and
transformed into a length density for the entire tumor.
Statistical Analysis
All of the statistical analyses were performed with a
statistical software package, using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego, CA). The
Mann-Whitney U test for two groups was applied to assess
the association between continuous variables. The 2 or
Fisher’s exact test for two groups was applied to assess the
association between categorical variables. Overall survival
curves were calculated with the Kaplan-Meier method and
compared by the log-rank test. A disease-free survival anal-
ysis could not be performed, as these data were not retract-
able for all patients. In case of multivariable logistic regres-
sion analysis and multivariable Cox regression survival
analysis, SAS software was used. Multicollinearity was as-
sessed using the Spearman correlation coefficient statistic.
Statistical significance was defined as p values 0.05. All p
values were two sided.
RESULTS
Patient Characteristics
In total, 91 patients with pathologic stages I and II
NSCLC were included in this analysis. There were 86% males
and 14% females, 74% stages I and 26% stage II patients, and
57% squamous cell carcinomas, 29% adenocarcinomas and
14% large cell carcinomas. A median tumor size of 3.8 cm
(range 0.9–10.5; mean 3.9 and SD 2.3) and 3.3 cm (range
1.0–9.5; mean 3.8 and SD 2.0) was obtained for tumors from
Leuven and Maastricht, respectively. The overall median fol-
low-up time was 41 months (range 1–95) and 61 months (range
29–95) in surviving patients.
Prognostic Value of SUVmax on FDG-PET
Univariable Kaplan-Meier survival analysis showed a
significantly worse survival when the SUVmax was  median
FIGURE 1. Kaplan-Meier overall survival curves according
to median SUVmax (A) and median PVC SUVmax (B).
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(hazard ratio 1.87, 95% confidence interval 1.09–3.34, p 
0.024; Figure 1A) and the PVC SUVmax was  median
(hazard ratio 2.08, 95% confidence interval 1.21–3.73, p 
0.0085; Figure 1B). In multivariable Cox regression analysis,
only PVC SUVmax remained significantly associated with
increased risk of death after correction for pTNM stage, age,
and T size (Table 1).
Associations of FDG Uptake with Tumor Size,
Histology, TNM-Stage, and N-Stage
Tumor size (as measured by the maximum diameter in
the pathologic resection specimen) was significantly associ-
ated with SUVmax (p 0.0001) and PVC SUVmax (p 0.03;
Table 2). Quantified FDG uptake was not significantly asso-
ciated with histology, TNM stage, or N-stage but showed a
trend (p  0.10) for association with TNM stage that disap-
peared after PVC.
Associations of FDG Uptake with Tumor Cell
Density and Tumor Architecture
The tumor cell density (expressed as the number of TC
per millimetre tumor) showed a significant association with
SUVmax (p  0.04) and even stronger association with PVC
SUVmax (p  0.007; Table 3). No association was found
between FDG uptake and components of tumor architecture
such as INF, necrosis, and fibroblastic connective tissue.
Associations of FDG Uptake with Different
Biologic Variables
Tables 4 and 5 summarize the univariable and multi-
variable analyses of the association between SUVmax and








II 1.45 (0.78–2.93) 1.16 (0.61–2.21) 1.23 (0.64–2.36)
Age (yr)
 median 1.74 (1.01–3.11) 1.43 (0.78–2.62) 1.42 (0.78–2.57)
T size
3 cm 1.73 (0.97–2.96) 1.19 (0.58–2.44) 1.30 (0.68–2.49)
SUVmax
 median 1.87 (1.09–3.34) 1.52 (0.79–2.94) —
PVC SUVmax
 median 2.08 (1.21–3.73) — 1.88 (1.05–3.37)
Reference categories HR 1: pTNM stage I, age  median, T size 3 cm, SUVmax  median, PVC SUVmax  median.
Multivariable model 1: SUVmax adjusted for pTNM stage, age, and T size.
Multivariable model 2: PVC SUVmax adjusted for pTNM stage, age, and T size.
HR, hazard ratio; CI, confidence interval; SUVmax, maximum pixel standardized uptake value; TNM, tumor, node,
metastasis; PVC, partial volume correction.
TABLE 2. Association of FDG Uptake and Tumor Size, Histology, and Pathological Stage
SUVmax PVC SUVmax
< Median > Median p < Median > Median p
T size
p-dia in cm 2.3 (1.5–3.5) 4.5 (3.6–5.8) 0.0001a 3.0 (2.1–4.5) 4.1 (2.5–5.8) 0.03a
Histology
Squamous 25 27 0.50b 24 28 0.31b
Adeno 15 11 16 10
Large cell 5 8 5 8
pTNM stage
Stage I 37 30 0.10c 34 33 0.81c
Stage II 8 16 11 13
pN stage
N0 41 38 0.35c 39 40 1.00c
N1 4 8 6 6
a Mann-Whitney U test: median (interquartile range).
b 2 test.
c Fisher’s Exact test.
FDG, 18F-fluoro-2-deoxy-d-glucose; SUVmax, maximum pixel standardized uptake value; TNM, tumor, node, metastasis;
PVC, partial volume correction.
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PVC SUVmax immunohistochemical biomarkers of different
tumor functions, respectively.
Ki-67 length density was significantly associated
with SUVmax (p  0.036) and even stronger with PVC
SUVmax (p  0.005). CAIX and HIF-1 length density
showed a trend (p  0.089 and p  0.12, respectively) for
an association with PVC SUVmax. No association was
found between quantitative FDG uptake and CD31 mi-
crovessel density.
The full model algorithm for logistic regression was
applied to Ki-67, CAIX, HIF-1, caspase-3, and CD31 length
density as five independent variables and quantitative FDG
uptake  median as dependent variable (Table 5). The
number of observations was 91, and the number of events per
variable was 9.2. The fit of the full model was assessed by the
Hosmer-Lemeshow goodness of fit, which was 8.5 (p 
0.38). After logistic regression analysis only a high Ki-67 and
high-CAIX length density met the 0.05 significance level to
explain a PVC SUVmax  median (Table 5).
DISCUSSION
In this study, we assessed the prognostic value of
FDG uptake in selected, i.e., pathologic stages I and II
patients with NSCLC and subsequently studied the rela-
tionship of quantitative FDG uptake to various character-
istics of tumor morphology and tumor vitality at a micro-
scopic level.
TABLE 3. Univariable Analysis of FDG Uptake and Quantitative Morphology on H&E
Sections
SUVmax PVC SUVmax
< Median > Median pa < Median > Median pa
n tumor cells/mmTC 65 (55–80) 75 (60–95) 0.041 65 (55–75) 80 (60–95) 0.007
% TC 46 (28–57) 38 (28–51) 0.32 42 (28–55) 43 (29–54) 0.83
% NEC 3 (0–15) 6 (3–16) 0.12 6 (0–16) 6 (1–16) 0.64
% INF 6 (3–14) 8 (2–16) 0.82 6 (2–15) 8 (3–15) 0.71
% FIB 31 (21–43) 33 (24–48) 0.51 32 (23–44) 31 (22–51) 0.91
a Mann-Whitney U test: median (interquartile range).
n, number; TC, tumor cells; NEC, necrosis; INF, inflammatory interstitium; FIB, fibroblastic connective tissue; FDG,
18F-fluoro-2-deoxy-d-glucose; H&E, hematoxylin and eosin; SUVmax, maximum pixel standardized uptake value; PVC, partial
volume correction.
TABLE 4. Univariable Analysis of FDG Uptake and Different Immunohistochemical
Markers
SUVmax PVC SUVmax
< Median > Median pa < Median > Median pa
n Ki-67/mmTC 18 (7–27) 22 (16–29) 0.036 16 (7–24) 23 (17–31) 0.005
n CAIX/mmTC 17 (9–25) 19 (11–31) 0.29 14 (8–23) 19 (11–33) 0.089
N HIF-1/mmTC 2 (0–9) 4 (0–15) 0.24 2 (0–9) 5 (0–15) 0.12
n caspase-3/mmTC 3 (0–8) 5 (2–9) 0.07 4 (0–9) 5 (1–8) 0.48
n CD31/mm tumor 10 (7–14) 11 (9–14) 0.42 10 (7–13) 11 (9–15) 0.23
a Mann-Whitney U test: median (interquartile range).
n, number; TC, tumor cells; HIF-1, hypoxia; Ki-67, cell proliferation; CAIX, carbonic anhydrase IX.
TABLE 5. Multivariable Logistic Regression Analysis of Immunohistochemical Markers
Independent Variable
Model 1: Dependent Variable:
SUVmax > Median
Model 2: Dependent Variable: PVC
SUVmax > Median
 p OR 95% CI  p OR 95% CI
n Ki-67/mm TC 0.04 0.10 1.04 0.99–1.09 0.06 0.02 1.06 1.01–1.11
n CAIX/mm TC 0.02 0.24 1.02 0.99–1.06 0.04 0.05 1.04 1.00–1.07
n HIF-1/mm TC 0.02 0.52 1.02 0.96–1.08 0.03 0.31 1.03 0.97–1.09
n caspase-3/mm TC 0.05 0.31 1.06 0.95–1.17 0.03 0.56 0.97 0.87–1.08
n CD31/mm tumor 0.02 0.73 1.02 0.93–1.10 0.02 0.63 1.02 0.94–1.12
Model 1, full model fitted: max R2  0.13, Wald 2  8.1, p  0.15.
Model 2, full model fitted: max R2  0.20, Wald 2  12, p  0.036.
HIF-1, hypoxia; Ki-67, cell proliferation; CAIX, carbonic anhydrase IX; CI, confidence interval; TC, tumor cells.
Dooms et al. Journal of Thoracic Oncology • Volume 4, Number 7, July 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer826
The major methodological limitations of our analysis
are related to the fact that older (e.g., cold transmission) PET
scanners were used and that each center had its specific
protocol (e.g., different FDG activities were injected, differ-
ent acquisition protocols). As the scanners and acquisition
protocols were standardized in each center, we assume that
we may overcome these limitations by dividing the patients
of each center into two groups based on the median SUV for
each center.
Our study confirms in univariable analysis that the
prognostic significance of quantitative FDG uptake for re-
sected stages I and II NSCLC without adjuvant chemother-
apy. As partial volume effects resulting from the limited
reconstructed resolution of a PET scanner may systematically
underestimate the SUVmax in small lesions12 and as 55% of
our patients had a primary tumor 3 cm, we decided to
consider both SUVmax and PVC SUVmax for multivariable
analysis. Moreover, the prognostic value of SUVmax can be
influenced by tumor size, which is a known prognostic factor
in NSCLC.20 We observed a strong significant association
between tumor size and SUVmax (p  0.0001), which clearly
weakened after PVC for SUVmax (p  0.03). Nevertheless,
PVC SUVmax remained significant as a prognostic factor for
overall survival in multivariable analysis for completely re-
sected stages I and II NSCLC.
Not only the proportion of TC, but also tumor cell
density was significantly associated with quantitative FDG
uptake; a significant association with SUVmax (p  0.04)
became stronger after PVC (p  0.007). Nevertheless, one
has to realize that the PVC algorithm used also may add some
error as the background SUV (set at 0.25 for normal lung
tissue surrounding the tumor) is not constant and as, due to
the retrospective nature of this series, absence of 4D-gating
precludes correction for respiratory movements. Although the
presence of necrosis or inflammatory interstitium may theo-
retically influence quantitative FDG uptake, SUVmax, or
PVC SUVmax were not associated with these tumor compart-
ments (Table 3).
The rationale to consider quantitative FDG uptake for
assessing tumor vitality is based on the link between cancer
biology and cancer biochemistry. A rapidly growing body of
molecular and biochemical evidence suggests that common
oncogenic signal transduction pathways underlie the mecha-
nisms that drive both an energy dependent malignant growth
signal and a fuel signal that forces the continuous cellular
uptake of glucose.21–24 Moreover, it is likely that O2-regu-
lated genes, of which HIF-1 is a central transcription factor,
are involved in the development of a more malignant pheno-
type.25 We have previously reported that the amount FDG
uptake on PET is significantly associated with the expression
of HIF-1,15 but found now only a trend for an association
(Table 4) that can be explained by the choice for a specific cut
off, which is the median value in this analysis compared with
a predefined 25% cut-off for HIF-1 previously. HIF-1
encodes for many proteins 24,26,27 such as glucose transporters
and glycolytic enzymes that are necessary to reprogram the
intracellular fate of glucose. The metabolic products of gly-
colysis cause intracellular acidosis that is potentially toxic for
the cancer cells and might result in cellular apoptosis,28 but
HIF-1 also encodes for membrane bound carbonic anhy-
drases, such as CAIX. In multivariable regression analysis,
we observed that a high-FDG uptake could be explained by
high Ki-67 length density, representing cancer cell prolifer-
ation that is a requirement for disease activity, and high-
CAIX length density, representing tumor pH regulation.
CAIX has both an enzymatic role contributing to the main-
tenance of a normal intracellular pH and acidification of the
extracellular environment, and a nonenzymatic role modulat-
ing cell adhesion and migration, thereby promoting a meta-
static potential and poor prognosis.29,30 In other words, a
high-CAIX length density under conditions of high intracel-
lular glucose availability can be considered an effective
tumor survival strategy reflecting a metastatic phenotype and
poor prognosis.
In conclusion, our study indicates that FDG-PET mea-
suring PVC SUVmax might have a prognostic role in com-
pletely resected pathologic stages I and II NSCLC. Whether
the baseline quantitative FDG uptake could have a value in
standard clinical practice for determining the indication of
postoperative adjuvant chemotherapy in stages I and II
NSCLC is a challenging question that deserves further study.
Our translational research enabled to better characterize the
relationship between PVC SUVmax and cancer biology, find-
ing that tumor cell density and biomarkers of cell prolifera-
tion (Ki-67 length density) and pH regulation (CAIX length
density) were associated with a high-FDG uptake. To further
understand the complex metabolic alterations and regulatory
mechanisms during glycolysis, it is necessary that membrane
receptors, key signaling pathways (PI3K-AKT, MYC and
RAS-MAPK), and downstream surrogate biomarkers are pro-
spectively analyzed together at the microscopic level.
ACKNOWLEDGMENTS
Supported by the Fonds voor Wetenschappelijk Onder-
zoek grant G.0134.04 (to C.D.) and EC FP6 funding LSHC-
CT-2004-505785 (to A.V.B.).
REFERENCES
1. Warburg O. The Metabolism of Tumours. London: Constable Press,
1930.
2. Ahuja V, Coleman R, Herndon J, Patz E. The prognostic significance of
fluorodeoxyglucose positron emission tomography imaging for patients
with non-small cell lung carcinoma. Cancer 1998;83:918–924.
3. Vansteenkiste JF, Stroobants S, Dupont P, et al. Prognostic importance
of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-
positron emission tomography scan in non-small cell lung cancer: an
analysis of 125 cases. J Clin Oncol 1999;17:3201–3206.
4. Cerfolio R, Bryant A, Ohja B, Bartolucci AA. The maximum standard-
ized uptake values on positron emission tomography of a non-small cell
lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc
Surg 2005;130:151–159.
5. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a
prognostic factor for inoperable non-small cell lung cancer. Eur J
Cancer 2005;41:1533–1541.
6. Berghmans T, Dusart M, Paesmans M, et al; European Lung Cancer
Working Party for the IASLC Lung Cancer Staging Project. Primary
tumor standardized uptake value (SUVmax) measured on fluorodeoxy-
glucose positron emission tomography (FDG-PET) is of prognostic
value for survival in non-small cell lung cancer (NSCLC). A systematic
review and meta-analysis by the European Lung Cancer Working Party
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 FDG-PET Associated with Prognosis and Tumor Vitality
Copyright © 2009 by the International Association for the Study of Lung Cancer 827
for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:
6–12.
7. Vesselle H, Freeman J, Wiens L, et al. Fluorodeoxyglucose uptake of
primary non-small cell lung cancer at positron emission tomography:
new contrary data on prognostic role. Clin cancer Res 2007;13:3255–
3263.
8. Downey R, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18
fluorodeoxyglucose positron emission tomographic maximal standard-
ized uptake value predicts survival independent of clinical but not
pathologic TNM staging of resected non-small cell lung cancer. J Tho-
rac Cardiovasc Surg 2007;133:1419–1427.
9. Nguyen X, Lee W, Chung J, et al. FDG uptake, glucose transporter
type1, and Ki-67 expressions in non-small cell lung cancer: correlations
and prognostic values. Eur J Radiol 2007;62:214–219.
10. Higashi K, Ueda Y, Sakurai A, et al. Correlation of GLUT-1 glucose
transporter expression with 18F-FDG uptake in non-small cell lung
cancer. Eur J Nucl Med 2000;27:1778–1785.
11. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA,
Glut-1, and Hexokinase-II expressions in cancers and inflammatory
lesions of the lung. Neoplasie 2005;7:369–379.
12. Vesselle H, Schmidt R, Pugsley J, et al. Lung cancer proliferation
correlates with F18-fluorodeoxyglucose uptake by positron emission
tomography. Clin Cancer Res 2000;6:3837–3844.
13. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the
proliferative potential of non-small cell lung cancer. J Nucl Med 2000;
41:85–92.
14. Sasaki M, Sugio K, Kuwabara Y, et al. Alterations of tumor suppressor
genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung
cancer. Ann Nucl Med 2003;17:189–196.
15. van Baardwijk A, Dooms C, van Suylen RJ, et al. The maximum uptake
of 18F-deoxyglucose on PET scan correlates with survival, hypoxia
inducible factor-1 and GLUT-1 in non-small cell lung cancer. Eur J
Cancer 2007;43:1392–1398.
16. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Mi-
yasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the
relationship between vascular density and glucose metabolism. J Com-
put Assist Tomogr 2002;26:185–190.
17. Koukourakis M, Giatromanolaki A, Harris A, Sivridis E. Comparison of
metabolic pathways between cancer cells and stromal cells in colorectal
carcinomas: a metabolic survival role for tumor-associated stroma.
Cancer Res 2006;66:632–637.
18. Weibel E. Stereological Methods: Practical Methods for Biological
Morphometry, Vol. 1 and 2. London: Academic Press, 1979.
19. Gundersen H, Bendtsen T, Korbo L, et al. Some new, simple and
efficient stereological methods and their use in pathological research and
diagnosis. APMIS 1988;96:379–394.
20. Mery C, Pappas A, Burt B, et al. Diameter of non-small cell lung cancer
correlates with long-term survival. Chest 2005;128:3255–3260.
21. Blum R, Jacob-Hirsch J, Amarglio N, Rechavi G, Kloog Y. RAS
inhibition in glioblastoma down-regulates hypoxia-inducible factor 1-,
causing glycolysis shutdown and cell death. Cancer Res 2005;65:999–
1006.
22. Elstrom R, Bauer D, Buzzai M, et al. Akt stimulates aerobic glycolysis
in cancer cells. Cancer Res 2004;64:3892–3899.
23. Dang C, Semenza G. Oncogenic alterations of metabolism. Trends
Biochem Sci 1999;24:68–72.
24. Lum JJ, Bui T, Gruber M, et al. The transcription factor HIF-1 plays a
critical role in the growth factor-dependent regulation of both aerobic
and anaerobic glycolysis. Genes Dev 2007;21:1037–1049.
25. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on
clinical outcome. Cancer Metastasis Rev 2007;26:225–239.
26. Semenza G, Jiang B, Leung S, et al. Hypoxia response elements in the
aldolase A, enolase 1, and lactate dehydrogenase A gene promoters
contain essential binding sites for hypoxia-inducible factor 1. J Biol
Chem 1996;271:32529–32537.
27. Wykoff C, Beasley N, Watson P, et al. Hypoxia-inducible expression of
tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075–7083.
28. Park H, Lyons J, Ohtsubo T, Song CW. Acidic environment causes
apoptosis by increasing caspase activity. Br J Cancer 1999;80:1892–
1897.
29. Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP. The role of
carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer
2005;41:2935–2947.
30. Schlappack O, Zimmerman A, Hill L. Glucose starvation and acidosis:
effect on experimental metastatic potential, DNA content and MTX
resistance of murine tumour cells. Br J Cancer 1991;64:663–670.
Dooms et al. Journal of Thoracic Oncology • Volume 4, Number 7, July 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer828
